There’s a new drug to treat Alzheimer’s disease, but those who might benefit from it know almost nothing about it, a new study shows.
In the spring of 2021, for the first time in decades, the U.S. Food and Drug Administration approved a new drug to treat Alzheimer’s disease. Enthusiasm for the drug, aducanumab, was swiftly eclipsed by concerns about efficacy, prohibitive cost and serious side effects.
Now, researchers from Keck Medicine of USC, the USC Leonard Davis School of Gerontology, the USC Schaeffer Center and the USC Price School of Public Policy have found older Americans most at risk for Alzheimer’s know little about aducanumab, despite the fact that an overwhelming majority of survey respondents said they were worried about Alzheimer’s disease.
To continue reading this story, click here.